Analysts Set Pediatrix Medical Group, Inc. (NYSE:MD) Price Target at $16.10

Shares of Pediatrix Medical Group, Inc. (NYSE:MD) have received a consensus recommendation of “Hold” from the five ratings firms that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $16.10.

Several analysts recently issued reports on the stock. StockNews.com lowered shares of Pediatrix Medical Group from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Truist Financial lifted their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Jefferies Financial Group upped their price target on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. UBS Group boosted their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, November 4th.

Pediatrix Medical Group Price Performance

Shares of NYSE MD opened at $14.80 on Friday. The firm has a market cap of $1.27 billion, a P/E ratio of -4.84, a PEG ratio of 2.11 and a beta of 1.57. Pediatrix Medical Group has a twelve month low of $6.62 and a twelve month high of $16.41. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. The company has a 50 day moving average of $13.73 and a 200 day moving average of $10.54.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.37 by $0.07. The company had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. Pediatrix Medical Group’s revenue for the quarter was up .9% on a year-over-year basis. During the same period last year, the company earned $0.29 EPS. As a group, research analysts expect that Pediatrix Medical Group will post 1.26 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Mary Ann E. Moore sold 8,108 shares of the business’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the completion of the transaction, the executive vice president now owns 135,810 shares in the company, valued at approximately $2,172,960. The trade was a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Mark S. Ordan sold 27,600 shares of the firm’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the sale, the director now owns 138,683 shares in the company, valued at approximately $2,128,784.05. This represents a 16.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Franklin Resources Inc. acquired a new position in Pediatrix Medical Group during the third quarter worth approximately $598,000. Barclays PLC lifted its holdings in shares of Pediatrix Medical Group by 302.9% during the third quarter. Barclays PLC now owns 142,087 shares of the company’s stock worth $1,646,000 after purchasing an additional 106,817 shares during the period. Geode Capital Management LLC grew its position in Pediatrix Medical Group by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,936,751 shares of the company’s stock valued at $22,452,000 after buying an additional 45,155 shares during the last quarter. M&T Bank Corp increased its stake in Pediatrix Medical Group by 20.1% in the 3rd quarter. M&T Bank Corp now owns 85,264 shares of the company’s stock valued at $988,000 after buying an additional 14,247 shares during the period. Finally, Jane Street Group LLC raised its position in Pediatrix Medical Group by 54.0% during the 3rd quarter. Jane Street Group LLC now owns 303,283 shares of the company’s stock worth $3,515,000 after buying an additional 106,332 shares during the last quarter. 97.71% of the stock is owned by hedge funds and other institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.